Adi Mohanty
Chief Executive Officer bei BIORA THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Aditya P.
Mohanty was the founder of EnCellX, Inc. founded in 2019, where he served as the Chief Executive Officer until 2021.
Currently, he is the Chief Executive Officer & Director at Biora Therapeutics, Inc. and a Director at Cell Cure Neurosciences Ltd.
Mr. Mohanty's former positions include President, Co-Chief Executive Officer & Director at Lineage Cell Therapeutics, Inc., Director at Asterias Biotherapeutics, Inc., Director at OncoCyte Corp., Vice President-Manufacturing & Operations at Transkaryotic Therapies, Inc. and Shire Human Genetic Therapies, Inc., and President-Regenerative Medicine at Shire Plc.
Mr. Mohanty's education includes a graduate degree from Clarkson University, an MBA from St. Mary's College (Indiana), and an undergraduate degree from National Institute of Technology Tiruchirappalli.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BIORA THERAPEUTICS, INC.
5,66% | 15.02.2024 | 1 539 492 ( 5,66% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Adi Mohanty
| Unternehmen | Position | Beginn |
|---|---|---|
| BIORA THERAPEUTICS, INC. | Chief Executive Officer | 08.11.2021 |
Cell Cure Neurosciences Ltd.
 Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | Director/Board Member | - |
Ehemalige bekannte Positionen von Adi Mohanty
| Unternehmen | Position | Ende |
|---|---|---|
EnCellX, Inc.
 EnCellX, Inc. BiotechnologyHealth Technology EnCellX, Inc. is a biotechnology company that operates in the field of biotechnology. The private company is based in San-Diego, CA and has subsidiaries in Israel. The company was founded by Aditya P. Mohanty. | Chief Executive Officer | 01.11.2021 |
| ONCOCYTE CORPORATION | Director/Board Member | 17.06.2020 |
| LINEAGE CELL THERAPEUTICS, INC. | Chief Executive Officer | 17.09.2018 |
| ASTERIAS BIOTHERAPEUTICS INC | Director/Board Member | 08.03.2018 |
| SHIRE | Corporate Officer/Principal | 01.01.2014 |
Ausbildung von Adi Mohanty
| Clarkson University | Graduate Degree |
| St. Mary's College (Indiana) | Masters Business Admin |
| National Institute of Technology Tiruchirappalli | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
| ONCOCYTE CORPORATION | Health Technology |
| BIORA THERAPEUTICS, INC. | Health Services |
| Private Unternehmen | 6 |
|---|---|
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Asterias Biotherapeutics, Inc.
 Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA. | Health Technology |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
EnCellX, Inc.
EnCellX, Inc. BiotechnologyHealth Technology EnCellX, Inc. is a biotechnology company that operates in the field of biotechnology. The private company is based in San-Diego, CA and has subsidiaries in Israel. The company was founded by Aditya P. Mohanty. | Health Technology |
